Oncotelic Therapeutics Engages IBN for Corporate Communications Strategy
TL;DR
Oncotelic Therapeutics gains strategic advantage by partnering with IBN for corporate communications, enhancing visibility for its Phase 3 pancreatic cancer drug and AI-driven pipeline.
Oncotelic Therapeutics employs its proprietary AI platform PDAOAI and 45% stake in GMP Bio to systematically advance multiple drug candidates through regulatory filings and clinical trials.
Oncotelic Therapeutics is developing innovative RNA-based treatments for pediatric cancers and rare diseases, potentially improving survival and quality of life for underserved patient populations.
Oncotelic's CEO Dr. Vuong Trieu, co-inventor of Abraxane, leads a company with 39 US patents and a joint venture capable of supporting 20 drug candidates.
Found this article helpful?
Share it with your network and spread the knowledge!
Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing RNA-based immunotherapy and targeted treatments for cancer and underserved diseases, has announced the selection of IBN to spearhead its corporate communications strategy. This partnership comes at a critical juncture as the company advances therapies for difficult-to-treat and rare conditions, including pediatric cancers and aggressive solid tumors.
The company's lead candidate, OT-101, is currently in a Phase 3 trial for pancreatic ductal adenocarcinoma, one of the most challenging oncology indications with limited treatment options. The engagement with IBN, part of the Dynamic Brand Portfolio that includes specialized communications platform BioMedWire, represents a strategic move to enhance Oncotelic's market presence and investor communications during this pivotal development phase.
Led by Chairman and CEO Dr. Vuong Trieu, co-inventor of the cancer drug Abraxane, Oncotelic is building a multi-asset pipeline supported by its proprietary AI platform PDAOAI. The company also maintains a 45% stake in GMP Biotechnology Limited, a joint venture with Dragon Capital Overseas Limited capable of supporting regulatory filings for up to 20 drug candidates. This diversified approach positions Oncotelic to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates.
The corporate communications strategy will leverage IBN's extensive network, which includes access to wire solutions via https://ibn.fm/PTeNg, article syndication to over 5,000 outlets, and social media distribution to millions of followers. This comprehensive approach aims to provide investors and stakeholders with timely updates on the company's progress, particularly as it advances through critical clinical milestones.
For ongoing updates and news relating to OTLC, the company maintains its newsroom available at https://ibn.fm/OTLC. The selection of IBN for corporate communications reflects the growing importance of strategic messaging in the biopharmaceutical sector, where clear communication of clinical progress and pipeline development can significantly impact investor confidence and market positioning.
Curated from InvestorBrandNetwork (IBN)
